Quantitative Analysis of Isoform Switching in Cancer.

SatuRn alternative splicing cancer differential transcript expression differential transcript usage isoform switching transcriptomics

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Jun 2023
Historique:
received: 19 04 2023
revised: 26 05 2023
accepted: 11 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Over the past 8 years, multiple studies examined the phenomenon of isoform switching in human cancers and discovered that isoform switching is widespread, with hundreds to thousands of such events per cancer type. Although all of these studies used slightly different definitions of isoform switching, which in part led to a rather poor overlap of their results, they all leveraged transcript usage, a proportion of the transcript's expression in the total expression level of the parent gene, to detect isoform switching. However, how changes in transcript usage correlate with changes in transcript expression is not sufficiently explored. In this article, we adopt the most common definition of isoform switching and use a state-of-the-art tool for the analysis of differential transcript usage, SatuRn, to detect isoform switching events in 12 cancer types. We analyze the detected events in terms of changes in transcript usage and the relationship between transcript usage and transcript expression on a global scale. The results of our analysis suggest that the relationship between changes in transcript usage and changes in transcript expression is far from straightforward, and that such quantitative information can be effectively used for prioritizing isoform switching events for downstream analyses.

Identifiants

pubmed: 37373214
pii: ijms241210065
doi: 10.3390/ijms241210065
pmc: PMC10298363
pii:
doi:

Substances chimiques

Protein Isoforms 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Russian Science Foundation
ID : 21-74-10061

Références

Elife. 2020 Aug 14;9:
pubmed: 32795391
F1000Res. 2018 Jun 27;7:952
pubmed: 30356428
Nucleic Acids Res. 2021 Jan 8;49(D1):D916-D923
pubmed: 33270111
Sci Rep. 2020 Sep 2;10(1):14453
pubmed: 32879328
Nat Rev Cancer. 2021 Jan;21(1):22-36
pubmed: 33082563
Nucleic Acids Res. 2015 Feb 18;43(3):1345-56
pubmed: 25578962
Nat Rev Genet. 2022 Nov;23(11):697-710
pubmed: 35821097
Cell Rep. 2017 Aug 29;20(9):2215-2226
pubmed: 28854369
Cell Death Dis. 2017 Dec 13;8(12):3216
pubmed: 29238043
Front Mol Biosci. 2021 Nov 23;8:726902
pubmed: 34888349
FEBS Lett. 2003 Oct 23;553(3):250-6
pubmed: 14572633
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
F1000Res. 2019 Feb 24;8:213
pubmed: 30906538
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474
pubmed: 32303702
NPJ Aging Mech Dis. 2021 Jan 4;7(1):2
pubmed: 33398016
Nat Biotechnol. 2017 Apr 11;35(4):314-316
pubmed: 28398314
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Front Immunol. 2021 Aug 13;12:707734
pubmed: 34484205
Mol Ther Nucleic Acids. 2022 Aug 17;29:749-768
pubmed: 36090744
Sci Rep. 2022 Jun 17;12(1):10276
pubmed: 35715539
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Nat Methods. 2019 Feb;16(2):163-166
pubmed: 30664774
Dev Cell. 2022 Aug 8;57(15):1833-1846.e6
pubmed: 35820415
Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1606-11
pubmed: 26798068
F1000Res. 2016 Jun 13;5:1356
pubmed: 28105305
Bioinformatics. 2021 Nov 5;37(21):3781-3787
pubmed: 34469510
Mol Cancer Res. 2017 Sep;15(9):1206-1220
pubmed: 28584021
Genome Res. 2012 Oct;22(10):2008-17
pubmed: 22722343
Genome Biol. 2013 Jul 01;14(7):R70
pubmed: 23815980
EMBO Rep. 2021 Dec 6;22(12):e53085
pubmed: 34779563
F1000Res. 2021 May 11;10:374
pubmed: 36762203
Cell. 2016 Feb 11;164(4):805-17
pubmed: 26871637
BMC Genomics. 2016 Mar 03;17:181
pubmed: 26939613
Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193
pubmed: 30655609
Cell. 2019 Sep 5;178(6):1465-1477.e17
pubmed: 31491388
Cell Death Dis. 2019 Feb 21;10(3):177
pubmed: 30792387
PLoS One. 2010 May 25;5(5):e10810
pubmed: 20520830
Cancer Res. 1995 Jun 15;55(12):2507-10
pubmed: 7780958

Auteurs

Georgii Dolgalev (G)

Institute of Biomedical Chemistry, Moscow 119281, Russia.

Ekaterina Poverennaya (E)

Institute of Biomedical Chemistry, Moscow 119281, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH